You are here: Industry Insights > Xeljanz

News List

XELJANZ (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis firstwordpharma
August 23, 2021
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA) in patients two years.
Pfizer’s JAK inhibitor Xeljanz shows benefit in COVID-19 pneumonia pharmatimes
June 21, 2021
Pfizer’s JAK inhibitor Xeljanz reduced the risk of severe outcomes in hospitalised adult patients with COVID-19 pneumonia who were not on ventilation, according to new study data.
Pharmacovigilance Risk Assessment Committee meeting highlights, June 2021 europeanpharmaceuticalreview
June 17, 2021
The European Medicines Agency (EMA)’s drug safety committee (PRAC) concluded three safety signal reviews, two for COVID-19 interventions, at its June meeting.
Pfizer's 4Q Revenues up 12% contractpharma
February 10, 2021
COVID-19 vaccine BNT162b2, which was granted an EUA in the U.S. in December 2020, contributed $154 million in sales in the quarter.
Pfizer get USFDA nod for XELJANZ (tofacitinib) to treat active polyarticular course juvenile idiopathic arthritis expresspharma
October 09, 2020
Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight.
Pfizer announces results from Xeljanz® Xr oral shift study biospectrumasia
June 19, 2019
Results to be Presented During a Late-Breaking Oral Session at the Annual European Congress of Rheumatology (EULAR 2019)
EMA follows FDA in putting Pfizer’s Xeljanz under the microscope for safety concerns fiercepharma
March 04, 2019
Xeljanz’s worrisome safety signal has been picked up across the pond. After the FDA issued an alert on the Pfizer blockbuster early this week, the European Medicines Agency said it's kicking off a review of its own.
Patients switch to lower dose of Pfizer’s RA pill after safety signal pharmaphorum
February 22, 2019
Pfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in a clinical study, after a safety signal emerged in the trial of patients at high risk of cardiovascular events.
One Woman's Case Gives New Hope Against Disfiguring Sarcoidosis drugs
December 27, 2018
In very preliminary findings, an existing rheumatoid arthritis drug appeared to cure one woman of a rare but potentially life-threatening condition known as sarcoidosis.....
Pfizer receives EU nod for Ulcerative Colitis drug XELJANZ biospectrumasia
August 02, 2018
XELJANZ is the first and only oral therapy and Janus kinase (JAK) inhibitor to be approved for this patient population

Previous page 1 2 Next page